|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:ageRange
|
12 years and older
|
|
gptkbp:allocates
|
Randomized
|
|
gptkbp:arms
|
gptkb:Placebo
gptkb:Tezepelumab
2
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:collaboratesWith
|
gptkb:Amgen
|
|
gptkbp:completedIn
|
September 30, 2021
|
|
gptkbp:conditionStudied
|
Severe Asthma
|
|
gptkbp:enrollment
|
1061
|
|
gptkbp:intervention
|
gptkb:Tezepelumab
Parallel Assignment
|
|
gptkbp:location
|
gptkb:Asia
gptkb:Europe
gptkb:United_States
|
|
gptkbp:mask
|
Double-blind
|
|
gptkbp:officialName
|
gptkb:A_Phase_3,_Randomized,_Double-blind,_Placebo-controlled_Study_to_Evaluate_the_Efficacy_and_Safety_of_Tezepelumab_in_Adults_and_Adolescents_With_Severe,_Uncontrolled_Asthma_(NAVIGATOR)
|
|
gptkbp:primaryCompletionDate
|
September 30, 2021
|
|
gptkbp:purpose
|
Treatment
|
|
gptkbp:recognizedBy
|
gptkb:NAVIGATOR
|
|
gptkbp:result
|
Annualized asthma exacerbation rate
|
|
gptkbp:secondaryOutcome
|
Change from baseline in ACQ-6 score
Change from baseline in AQLQ(S)+12 score
Change from baseline in pre-bronchodilator FEV1
|
|
gptkbp:sponsor
|
gptkb:AstraZeneca
|
|
gptkbp:startDate
|
March 28, 2019
|
|
gptkbp:studyType
|
Interventional
|
|
gptkbp:bfsParent
|
gptkb:CLARITY
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NCT03887455
|